Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BG-C0902
- Development stage
- Phase 1
- Lead developer
- BeOne Medicines
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BG-C0902 is a bispecific antibody-drug conjugate (ADC) developed by BeOne Medicines for the treatment of advanced solid tumors. It consists of a fully humanized bispecific antibody targeting both the Epidermal Growth Factor Receptor (EGFR) and the Hepatocyte Growth Factor Receptor (MET). The antibody is conjugated via an enzymatically cleavable linker to a topoisomerase 1 (TOPO1) inhibitor payload. By simultaneously targeting EGFR and MET, BG-C0902 is designed to overcome resistance mechanisms often encountered with single-target therapies, particularly in tumors where these pathways are co-activated or where one pathway compensates for the inhibition of the other. The drug is currently undergoing Phase 1a/1b clinical evaluation to assess its safety, pharmacokinetics, and preliminary antitumor activity in patients with advanced solid tumors.
02
Targets
EGFR (Epidermal growth factor receptor)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on BG-C0902.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BG-C0902.